Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Chengdu Keymed Starts China Trial of Bispecific for Solid Tumor Cancers

publication date: Jun 10, 2022

Chengdu Keymed Biosciences dosed the first patient in a China Phase I trial of a bispecific antibody that targets solid tumors. CM350,which was developed on Keymed’s proprietary Novel T cell engager platform, is the first GPC3xCD3 to start China trials. GPC3 expression is rarely found in normal human adult tissues but upregulated in many types of solid tumors including hepatocellular carcinoma along with lung, gastric and esophageal cancers. The Phase I trial will evaluate safety issues and preliminary antitumor activity of CM350 in patients with solid tumors. Keymed develops novel drugs for autoimmune diseases and cancer. More details....

Stock Symbol: (HK: 02162)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here